Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · IEX Real-Time Price · USD
51.54
-3.78 (-6.83%)
At close: Jul 2, 2024, 4:00 PM
51.77
+0.23 (0.45%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Viking Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
27
Market Cap
5.68B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Organon & Co. | 6.35B |
Acadia Healthcare Company | 2.99B |
R1 RCM | 2.31B |
Lantheus Holdings | 1.37B |
Tempus AI | 562.02M |
Glaukos | 326.43M |
Revolution Medicines | 4.57M |
Cytokinetics | 3.75M |
VKTX News
- 8 days ago - Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association - PRNewsWire
- 4 weeks ago - Viking Therapeutics reports promising data for liver disease drug - Invezz
- 4 weeks ago - Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) - PRNewsWire
- 4 weeks ago - Viking Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance - CNBC
- 2 months ago - Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX - Invezz
- 2 months ago - Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 - PRNewsWire